Modelling NAFLD disease burden in four Asian regions-2019-2030
- PMID: 32133676
- PMCID: PMC7154715
- DOI: 10.1111/apt.15673
Modelling NAFLD disease burden in four Asian regions-2019-2030
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia-Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations.
Aims: To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are most likely to experience advanced liver disease and related mortality.
Methods: A disease progression model was used to summarise and project fibrosis progression among the NAFLD populations of Hong Kong, Singapore, South Korea and Taiwan. For each area, changes in the adult prevalence of obesity was used to extrapolate long-term trends in NAFLD incidence.
Results: In the areas studied, prevalent NAFLD cases were projected to increase 6%-20% during 2019-2030, while prevalent NASH cases increase 20%-35%. Incident cases of hepatocellular carcinoma are projected to increase by 65%-85%, while incident decompensated cirrhosis cases increase 65%-100% by 2030. Likewise, NAFLD-related mortality is projected to increase between 65% and 100% from 2019 to 2030. NAFLD disease burden is expected to increase alongside rising trends in metabolic syndrome and obesity among populations in the region. This leads to more cases of advanced liver disease and associated mortality.
Conclusions: Preventing the growth of diabetic and obese populations will be a key factor in reducing ongoing increases in NAFLD-related disease burden in the Asia-Pacific region.
© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Figures



Comment in
-
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action.Aliment Pharmacol Ther. 2020 Jun;51(12):1429-1430. doi: 10.1111/apt.15700. Aliment Pharmacol Ther. 2020. PMID: 32445522 No abstract available.
-
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors' reply.Aliment Pharmacol Ther. 2020 Jun;51(12):1430-1432. doi: 10.1111/apt.15718. Aliment Pharmacol Ther. 2020. PMID: 32445526 No abstract available.
-
Letter: Hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma.Aliment Pharmacol Ther. 2021 Sep;54(5):736-737. doi: 10.1111/apt.16532. Aliment Pharmacol Ther. 2021. PMID: 34379831 No abstract available.
References
-
- Korean Association for the Study of the Liver . Liver Disease White Paper 2013; 2013; http://www.kasl.org/bbs/index.html?code=ency%26category=%26gubun=%26idx=.... Accessed 29 August, 2019.
-
- Wong VW, Chan WK, Chitturi S, et al. Asia‐Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017‐Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70‐85. - PubMed
-
- Chan WK, Treeprasertsuk S, Imajo K, et al. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region‐the GO ASIA initiative. Aliment Pharmacol Ther. 2018;47(6):816‐825. - PubMed
-
- Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862‐873. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical